IBDEI03Q ; ; 01-AUG-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;AUG 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,8942,1,4,0)
 ;;=4^D63.0
 ;;^UTILITY(U,$J,358.3,8942,2)
 ;;=^321978
 ;;^UTILITY(U,$J,358.3,8943,0)
 ;;=D63.8^^45^431^22
 ;;^UTILITY(U,$J,358.3,8943,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8943,1,3,0)
 ;;=3^Anemia in Chronic Diseases Classified Elsewhere
 ;;^UTILITY(U,$J,358.3,8943,1,4,0)
 ;;=4^D63.8
 ;;^UTILITY(U,$J,358.3,8943,2)
 ;;=^5002343
 ;;^UTILITY(U,$J,358.3,8944,0)
 ;;=C22.3^^45^431^27
 ;;^UTILITY(U,$J,358.3,8944,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8944,1,3,0)
 ;;=3^Angiosarcoma of Liver
 ;;^UTILITY(U,$J,358.3,8944,1,4,0)
 ;;=4^C22.3
 ;;^UTILITY(U,$J,358.3,8944,2)
 ;;=^5000936
 ;;^UTILITY(U,$J,358.3,8945,0)
 ;;=D61.9^^45^431^28
 ;;^UTILITY(U,$J,358.3,8945,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8945,1,3,0)
 ;;=3^Aplastic Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,8945,1,4,0)
 ;;=4^D61.9
 ;;^UTILITY(U,$J,358.3,8945,2)
 ;;=^5002342
 ;;^UTILITY(U,$J,358.3,8946,0)
 ;;=D56.1^^45^431^34
 ;;^UTILITY(U,$J,358.3,8946,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8946,1,3,0)
 ;;=3^Beta Thalassemia
 ;;^UTILITY(U,$J,358.3,8946,1,4,0)
 ;;=4^D56.1
 ;;^UTILITY(U,$J,358.3,8946,2)
 ;;=^340495
 ;;^UTILITY(U,$J,358.3,8947,0)
 ;;=C83.79^^45^431^36
 ;;^UTILITY(U,$J,358.3,8947,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8947,1,3,0)
 ;;=3^Burkitt Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,8947,1,4,0)
 ;;=4^C83.79
 ;;^UTILITY(U,$J,358.3,8947,2)
 ;;=^5001600
 ;;^UTILITY(U,$J,358.3,8948,0)
 ;;=C83.70^^45^431^37
 ;;^UTILITY(U,$J,358.3,8948,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8948,1,3,0)
 ;;=3^Burkitt Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,8948,1,4,0)
 ;;=4^C83.70
 ;;^UTILITY(U,$J,358.3,8948,2)
 ;;=^5001591
 ;;^UTILITY(U,$J,358.3,8949,0)
 ;;=D09.0^^45^431^44
 ;;^UTILITY(U,$J,358.3,8949,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8949,1,3,0)
 ;;=3^Carcinoma in Situ of Bladder
 ;;^UTILITY(U,$J,358.3,8949,1,4,0)
 ;;=4^D09.0
 ;;^UTILITY(U,$J,358.3,8949,2)
 ;;=^267742
 ;;^UTILITY(U,$J,358.3,8950,0)
 ;;=D06.9^^45^431^45
 ;;^UTILITY(U,$J,358.3,8950,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8950,1,3,0)
 ;;=3^Carcinoma in Situ of Cervix
 ;;^UTILITY(U,$J,358.3,8950,1,4,0)
 ;;=4^D06.9
 ;;^UTILITY(U,$J,358.3,8950,2)
 ;;=^5001941
 ;;^UTILITY(U,$J,358.3,8951,0)
 ;;=D06.0^^45^431^47
 ;;^UTILITY(U,$J,358.3,8951,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8951,1,3,0)
 ;;=3^Carcinoma in Situ of Endocervix
 ;;^UTILITY(U,$J,358.3,8951,1,4,0)
 ;;=4^D06.0
 ;;^UTILITY(U,$J,358.3,8951,2)
 ;;=^5001938
 ;;^UTILITY(U,$J,358.3,8952,0)
 ;;=D06.1^^45^431^48
 ;;^UTILITY(U,$J,358.3,8952,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8952,1,3,0)
 ;;=3^Carcinoma in Situ of Exocervix
 ;;^UTILITY(U,$J,358.3,8952,1,4,0)
 ;;=4^D06.1
 ;;^UTILITY(U,$J,358.3,8952,2)
 ;;=^5001939
 ;;^UTILITY(U,$J,358.3,8953,0)
 ;;=D06.7^^45^431^46
 ;;^UTILITY(U,$J,358.3,8953,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8953,1,3,0)
 ;;=3^Carcinoma in Situ of Cervix,Other Parts
 ;;^UTILITY(U,$J,358.3,8953,1,4,0)
 ;;=4^D06.7
 ;;^UTILITY(U,$J,358.3,8953,2)
 ;;=^5001940
 ;;^UTILITY(U,$J,358.3,8954,0)
 ;;=D04.9^^45^431^49
 ;;^UTILITY(U,$J,358.3,8954,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8954,1,3,0)
 ;;=3^Carcinoma in Situ of Skin
 ;;^UTILITY(U,$J,358.3,8954,1,4,0)
 ;;=4^D04.9
 ;;^UTILITY(U,$J,358.3,8954,2)
 ;;=^5001925
 ;;^UTILITY(U,$J,358.3,8955,0)
 ;;=C91.11^^45^431^52
 ;;^UTILITY(U,$J,358.3,8955,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8955,1,3,0)
 ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,In Remission
 ;;^UTILITY(U,$J,358.3,8955,1,4,0)
 ;;=4^C91.11
 ;;^UTILITY(U,$J,358.3,8955,2)
 ;;=^5001766
 ;;^UTILITY(U,$J,358.3,8956,0)
 ;;=C91.10^^45^431^53
 ;;^UTILITY(U,$J,358.3,8956,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8956,1,3,0)
 ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,Not in Remission
 ;;^UTILITY(U,$J,358.3,8956,1,4,0)
 ;;=4^C91.10
 ;;^UTILITY(U,$J,358.3,8956,2)
 ;;=^5001765
 ;;^UTILITY(U,$J,358.3,8957,0)
 ;;=C92.11^^45^431^54
 ;;^UTILITY(U,$J,358.3,8957,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8957,1,3,0)
 ;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,In Remission
 ;;^UTILITY(U,$J,358.3,8957,1,4,0)
 ;;=4^C92.11
 ;;^UTILITY(U,$J,358.3,8957,2)
 ;;=^5001793
 ;;^UTILITY(U,$J,358.3,8958,0)
 ;;=C92.10^^45^431^55
 ;;^UTILITY(U,$J,358.3,8958,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8958,1,3,0)
 ;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,Not in Remission
 ;;^UTILITY(U,$J,358.3,8958,1,4,0)
 ;;=4^C92.10
 ;;^UTILITY(U,$J,358.3,8958,2)
 ;;=^5001792
 ;;^UTILITY(U,$J,358.3,8959,0)
 ;;=D47.1^^45^431^56
 ;;^UTILITY(U,$J,358.3,8959,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8959,1,3,0)
 ;;=3^Chronic Myeloproliferative Disease
 ;;^UTILITY(U,$J,358.3,8959,1,4,0)
 ;;=4^D47.1
 ;;^UTILITY(U,$J,358.3,8959,2)
 ;;=^5002256
 ;;^UTILITY(U,$J,358.3,8960,0)
 ;;=C82.69^^45^431^57
 ;;^UTILITY(U,$J,358.3,8960,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8960,1,3,0)
 ;;=3^Cutaneous Follicle Center Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,8960,1,4,0)
 ;;=4^C82.69
 ;;^UTILITY(U,$J,358.3,8960,2)
 ;;=^5001530
 ;;^UTILITY(U,$J,358.3,8961,0)
 ;;=C82.60^^45^431^58
 ;;^UTILITY(U,$J,358.3,8961,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8961,1,3,0)
 ;;=3^Cutaneous Follicle Center Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,8961,1,4,0)
 ;;=4^C82.60
 ;;^UTILITY(U,$J,358.3,8961,2)
 ;;=^5001521
 ;;^UTILITY(U,$J,358.3,8962,0)
 ;;=D56.2^^45^431^59
 ;;^UTILITY(U,$J,358.3,8962,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8962,1,3,0)
 ;;=3^Delta-Beta Thalassemia
 ;;^UTILITY(U,$J,358.3,8962,1,4,0)
 ;;=4^D56.2
 ;;^UTILITY(U,$J,358.3,8962,2)
 ;;=^340496
 ;;^UTILITY(U,$J,358.3,8963,0)
 ;;=D75.9^^45^431^60
 ;;^UTILITY(U,$J,358.3,8963,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8963,1,3,0)
 ;;=3^Disease of Blood/Blood-Forming Organs,Unspec
 ;;^UTILITY(U,$J,358.3,8963,1,4,0)
 ;;=4^D75.9
 ;;^UTILITY(U,$J,358.3,8963,2)
 ;;=^5002393
 ;;^UTILITY(U,$J,358.3,8964,0)
 ;;=D59.0^^45^431^63
 ;;^UTILITY(U,$J,358.3,8964,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8964,1,3,0)
 ;;=3^Drug-Induced Autoimmune Hemolytic Anemia
 ;;^UTILITY(U,$J,358.3,8964,1,4,0)
 ;;=4^D59.0
 ;;^UTILITY(U,$J,358.3,8964,2)
 ;;=^5002323
 ;;^UTILITY(U,$J,358.3,8965,0)
 ;;=D59.2^^45^431^64
 ;;^UTILITY(U,$J,358.3,8965,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8965,1,3,0)
 ;;=3^Drug-Induced Nonautoimmune Hemolytic Anemia
 ;;^UTILITY(U,$J,358.3,8965,1,4,0)
 ;;=4^D59.2
 ;;^UTILITY(U,$J,358.3,8965,2)
 ;;=^5002325
 ;;^UTILITY(U,$J,358.3,8966,0)
 ;;=R59.9^^45^431^67
 ;;^UTILITY(U,$J,358.3,8966,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8966,1,3,0)
 ;;=3^Enlarged Lymph Nodes,Unspec
 ;;^UTILITY(U,$J,358.3,8966,1,4,0)
 ;;=4^R59.9
 ;;^UTILITY(U,$J,358.3,8966,2)
 ;;=^5019531
 ;;^UTILITY(U,$J,358.3,8967,0)
 ;;=D47.3^^45^431^68
 ;;^UTILITY(U,$J,358.3,8967,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8967,1,3,0)
 ;;=3^Essential Thrombocythemia
 ;;^UTILITY(U,$J,358.3,8967,1,4,0)
 ;;=4^D47.3
 ;;^UTILITY(U,$J,358.3,8967,2)
 ;;=^5002258
 ;;^UTILITY(U,$J,358.3,8968,0)
 ;;=C82.09^^45^431^69
 ;;^UTILITY(U,$J,358.3,8968,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8968,1,3,0)
 ;;=3^Follicular Lymphoma Grade I,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,8968,1,4,0)
 ;;=4^C82.09
 ;;^UTILITY(U,$J,358.3,8968,2)
 ;;=^5001470
 ;;^UTILITY(U,$J,358.3,8969,0)
 ;;=C82.00^^45^431^70
 ;;^UTILITY(U,$J,358.3,8969,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8969,1,3,0)
 ;;=3^Follicular Lymphoma Grade I,Unspec Site
 ;;^UTILITY(U,$J,358.3,8969,1,4,0)
 ;;=4^C82.00
 ;;^UTILITY(U,$J,358.3,8969,2)
 ;;=^5001461
 ;;^UTILITY(U,$J,358.3,8970,0)
 ;;=C82.19^^45^431^71
 ;;^UTILITY(U,$J,358.3,8970,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8970,1,3,0)
 ;;=3^Follicular Lymphoma Grade II,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,8970,1,4,0)
 ;;=4^C82.19
 ;;^UTILITY(U,$J,358.3,8970,2)
 ;;=^5001480
 ;;^UTILITY(U,$J,358.3,8971,0)
 ;;=C82.10^^45^431^72
 ;;^UTILITY(U,$J,358.3,8971,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8971,1,3,0)
 ;;=3^Follicular Lymphoma Grade II,Unspec Site
 ;;^UTILITY(U,$J,358.3,8971,1,4,0)
 ;;=4^C82.10
 ;;^UTILITY(U,$J,358.3,8971,2)
 ;;=^5001471
 ;;^UTILITY(U,$J,358.3,8972,0)
 ;;=C82.29^^45^431^73
 ;;^UTILITY(U,$J,358.3,8972,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8972,1,3,0)
 ;;=3^Follicular Lymphoma Grade III,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,8972,1,4,0)
 ;;=4^C82.29
 ;;^UTILITY(U,$J,358.3,8972,2)
 ;;=^5001490
 ;;^UTILITY(U,$J,358.3,8973,0)
 ;;=C82.20^^45^431^74
 ;;^UTILITY(U,$J,358.3,8973,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8973,1,3,0)
 ;;=3^Follicular Lymphoma Grade III,Unspec Site
 ;;^UTILITY(U,$J,358.3,8973,1,4,0)
 ;;=4^C82.20
 ;;^UTILITY(U,$J,358.3,8973,2)
 ;;=^5001481
 ;;^UTILITY(U,$J,358.3,8974,0)
 ;;=C82.39^^45^431^75
 ;;^UTILITY(U,$J,358.3,8974,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8974,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIa,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,8974,1,4,0)
 ;;=4^C82.39
 ;;^UTILITY(U,$J,358.3,8974,2)
 ;;=^5001500
 ;;^UTILITY(U,$J,358.3,8975,0)
 ;;=C82.30^^45^431^76
 ;;^UTILITY(U,$J,358.3,8975,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8975,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIa,Unspec Site
 ;;^UTILITY(U,$J,358.3,8975,1,4,0)
 ;;=4^C82.30
 ;;^UTILITY(U,$J,358.3,8975,2)
 ;;=^5001491
 ;;^UTILITY(U,$J,358.3,8976,0)
 ;;=C82.49^^45^431^77
 ;;^UTILITY(U,$J,358.3,8976,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8976,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIb,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,8976,1,4,0)
 ;;=4^C82.49
 ;;^UTILITY(U,$J,358.3,8976,2)
 ;;=^5001510
 ;;^UTILITY(U,$J,358.3,8977,0)
 ;;=C82.40^^45^431^78
 ;;^UTILITY(U,$J,358.3,8977,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8977,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIb,Unspec Site
 ;;^UTILITY(U,$J,358.3,8977,1,4,0)
 ;;=4^C82.40
 ;;^UTILITY(U,$J,358.3,8977,2)
 ;;=^5001501
 ;;^UTILITY(U,$J,358.3,8978,0)
 ;;=C82.99^^45^431^79
 ;;^UTILITY(U,$J,358.3,8978,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8978,1,3,0)
 ;;=3^Follicular Lymphoma Unspec,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,8978,1,4,0)
 ;;=4^C82.99
 ;;^UTILITY(U,$J,358.3,8978,2)
 ;;=^5001550
 ;;^UTILITY(U,$J,358.3,8979,0)
 ;;=C82.90^^45^431^80
 ;;^UTILITY(U,$J,358.3,8979,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8979,1,3,0)
 ;;=3^Follicular Lymphoma Unspec,Unspec Site
 ;;^UTILITY(U,$J,358.3,8979,1,4,0)
 ;;=4^C82.90
 ;;^UTILITY(U,$J,358.3,8979,2)
 ;;=^5001541
 ;;^UTILITY(U,$J,358.3,8980,0)
 ;;=R59.1^^45^431^65
 ;;^UTILITY(U,$J,358.3,8980,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8980,1,3,0)
 ;;=3^Enlarged Lymph Nodes,Generalized
 ;;^UTILITY(U,$J,358.3,8980,1,4,0)
 ;;=4^R59.1
 ;;^UTILITY(U,$J,358.3,8980,2)
 ;;=^5019530
 ;;^UTILITY(U,$J,358.3,8981,0)
 ;;=C91.40^^45^431^84
 ;;^UTILITY(U,$J,358.3,8981,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8981,1,3,0)
 ;;=3^Hairy Cell Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,8981,1,4,0)
 ;;=4^C91.40
 ;;^UTILITY(U,$J,358.3,8981,2)
 ;;=^5001771
 ;;^UTILITY(U,$J,358.3,8982,0)
 ;;=C91.42^^45^431^82
 ;;^UTILITY(U,$J,358.3,8982,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8982,1,3,0)
 ;;=3^Hairy Cell Leukemia,In Relapse
 ;;^UTILITY(U,$J,358.3,8982,1,4,0)
 ;;=4^C91.42
 ;;^UTILITY(U,$J,358.3,8982,2)
 ;;=^5001773
 ;;^UTILITY(U,$J,358.3,8983,0)
 ;;=C91.41^^45^431^83
 ;;^UTILITY(U,$J,358.3,8983,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8983,1,3,0)
 ;;=3^Hairy Cell Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,8983,1,4,0)
 ;;=4^C91.41
 ;;^UTILITY(U,$J,358.3,8983,2)
 ;;=^5001772
 ;;^UTILITY(U,$J,358.3,8984,0)
 ;;=D57.01^^45^431^85
 ;;^UTILITY(U,$J,358.3,8984,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8984,1,3,0)
 ;;=3^Hb-SS Disease w/ Acute Chest Syndrome
 ;;^UTILITY(U,$J,358.3,8984,1,4,0)
 ;;=4^D57.01
 ;;^UTILITY(U,$J,358.3,8984,2)
 ;;=^5002307
 ;;^UTILITY(U,$J,358.3,8985,0)
 ;;=D57.00^^45^431^86
 ;;^UTILITY(U,$J,358.3,8985,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8985,1,3,0)
 ;;=3^Hb-SS Disease w/ Crisis,Unspec
 ;;^UTILITY(U,$J,358.3,8985,1,4,0)
 ;;=4^D57.00
 ;;^UTILITY(U,$J,358.3,8985,2)
 ;;=^5002306
 ;;^UTILITY(U,$J,358.3,8986,0)
 ;;=D57.02^^45^431^87
 ;;^UTILITY(U,$J,358.3,8986,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8986,1,3,0)
 ;;=3^Hb-SS Disease w/ Splenic Sequestration
 ;;^UTILITY(U,$J,358.3,8986,1,4,0)
 ;;=4^D57.02
 ;;^UTILITY(U,$J,358.3,8986,2)
 ;;=^5002308
 ;;^UTILITY(U,$J,358.3,8987,0)
 ;;=D68.32^^45^431^89
 ;;^UTILITY(U,$J,358.3,8987,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8987,1,3,0)
 ;;=3^Hemorrhagic Disorder d/t Extrinsic Circulating Anticoagulants
 ;;^UTILITY(U,$J,358.3,8987,1,4,0)
 ;;=4^D68.32
 ;;^UTILITY(U,$J,358.3,8987,2)
 ;;=^5002357
 ;;^UTILITY(U,$J,358.3,8988,0)
 ;;=C22.2^^45^431^90
 ;;^UTILITY(U,$J,358.3,8988,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8988,1,3,0)
 ;;=3^Hepatoblastoma
 ;;^UTILITY(U,$J,358.3,8988,1,4,0)
 ;;=4^C22.2
 ;;^UTILITY(U,$J,358.3,8988,2)
 ;;=^5000935
 ;;^UTILITY(U,$J,358.3,8989,0)
 ;;=D58.9^^45^431^92
 ;;^UTILITY(U,$J,358.3,8989,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8989,1,3,0)
 ;;=3^Hereditary Hemolytic Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,8989,1,4,0)
 ;;=4^D58.9
 ;;^UTILITY(U,$J,358.3,8989,2)
 ;;=^5002322
 ;;^UTILITY(U,$J,358.3,8990,0)
 ;;=C81.99^^45^431^93
 ;;^UTILITY(U,$J,358.3,8990,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8990,1,3,0)
 ;;=3^Hodgkin Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,8990,1,4,0)
 ;;=4^C81.99
 ;;^UTILITY(U,$J,358.3,8990,2)
 ;;=^5001460
 ;;^UTILITY(U,$J,358.3,8991,0)
 ;;=C81.90^^45^431^94
 ;;^UTILITY(U,$J,358.3,8991,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8991,1,3,0)
 ;;=3^Hodgkin Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,8991,1,4,0)
 ;;=4^C81.90
 ;;^UTILITY(U,$J,358.3,8991,2)
 ;;=^5001451
 ;;^UTILITY(U,$J,358.3,8992,0)
 ;;=D89.2^^45^431^95
 ;;^UTILITY(U,$J,358.3,8992,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8992,1,3,0)
 ;;=3^Hypergammaglobulenemia,Unspec
 ;;^UTILITY(U,$J,358.3,8992,1,4,0)
 ;;=4^D89.2
 ;;^UTILITY(U,$J,358.3,8992,2)
 ;;=^5002455
 ;;^UTILITY(U,$J,358.3,8993,0)
 ;;=D05.12^^45^431^98
 ;;^UTILITY(U,$J,358.3,8993,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8993,1,3,0)
 ;;=3^Intraductal Carcinoma in Situ,Left Breast
 ;;^UTILITY(U,$J,358.3,8993,1,4,0)
 ;;=4^D05.12
 ;;^UTILITY(U,$J,358.3,8993,2)
 ;;=^5001931
 ;;^UTILITY(U,$J,358.3,8994,0)
 ;;=D05.11^^45^431^99
 ;;^UTILITY(U,$J,358.3,8994,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8994,1,3,0)
 ;;=3^Intraductal Carcinoma in Situ,Right Breast
 ;;^UTILITY(U,$J,358.3,8994,1,4,0)
 ;;=4^D05.11
 ;;^UTILITY(U,$J,358.3,8994,2)
 ;;=^5001930
 ;;^UTILITY(U,$J,358.3,8995,0)
 ;;=D05.10^^45^431^100
 ;;^UTILITY(U,$J,358.3,8995,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8995,1,3,0)
 ;;=3^Intraductal Carcinoma in Situ,Unspec Breast
 ;;^UTILITY(U,$J,358.3,8995,1,4,0)
 ;;=4^D05.10
 ;;^UTILITY(U,$J,358.3,8995,2)
 ;;=^5001929
 ;;^UTILITY(U,$J,358.3,8996,0)
 ;;=D50.0^^45^431^101
 ;;^UTILITY(U,$J,358.3,8996,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8996,1,3,0)
 ;;=3^Iron Deficiency Anemia Secondary to Blood Loss
 ;;^UTILITY(U,$J,358.3,8996,1,4,0)
 ;;=4^D50.0
 ;;^UTILITY(U,$J,358.3,8996,2)
 ;;=^267971
 ;;^UTILITY(U,$J,358.3,8997,0)
 ;;=D50.9^^45^431^102
 ;;^UTILITY(U,$J,358.3,8997,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8997,1,3,0)
 ;;=3^Iron Deficiency Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,8997,1,4,0)
 ;;=4^D50.9
 ;;^UTILITY(U,$J,358.3,8997,2)
 ;;=^5002283
 ;;^UTILITY(U,$J,358.3,8998,0)
 ;;=C46.9^^45^431^103
 ;;^UTILITY(U,$J,358.3,8998,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8998,1,3,0)
 ;;=3^Kaposi's Sarcoma,Unspec
 ;;^UTILITY(U,$J,358.3,8998,1,4,0)
 ;;=4^C46.9
 ;;^UTILITY(U,$J,358.3,8998,2)
 ;;=^5001108
 ;;^UTILITY(U,$J,358.3,8999,0)
 ;;=C22.0^^45^431^104
 ;;^UTILITY(U,$J,358.3,8999,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8999,1,3,0)
 ;;=3^Liver Cell Carcinoma
 ;;^UTILITY(U,$J,358.3,8999,1,4,0)
 ;;=4^C22.0
 ;;^UTILITY(U,$J,358.3,8999,2)
 ;;=^5000933
 ;;^UTILITY(U,$J,358.3,9000,0)
 ;;=D05.02^^45^431^105
 ;;^UTILITY(U,$J,358.3,9000,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9000,1,3,0)
 ;;=3^Lobular Carcinoma in Situ,Left Breast
 ;;^UTILITY(U,$J,358.3,9000,1,4,0)
 ;;=4^D05.02
 ;;^UTILITY(U,$J,358.3,9000,2)
 ;;=^5001928
 ;;^UTILITY(U,$J,358.3,9001,0)
 ;;=D05.01^^45^431^106
 ;;^UTILITY(U,$J,358.3,9001,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9001,1,3,0)
 ;;=3^Lobular Carcinoma in Situ,Right Breast
 ;;^UTILITY(U,$J,358.3,9001,1,4,0)
 ;;=4^D05.01
 ;;^UTILITY(U,$J,358.3,9001,2)
 ;;=^5001927
 ;;^UTILITY(U,$J,358.3,9002,0)
 ;;=D05.00^^45^431^107
 ;;^UTILITY(U,$J,358.3,9002,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9002,1,3,0)
 ;;=3^Lobular Carcinoma in Situ,Unspec Breast
 ;;^UTILITY(U,$J,358.3,9002,1,4,0)
 ;;=4^D05.00
 ;;^UTILITY(U,$J,358.3,9002,2)
 ;;=^5001926
 ;;^UTILITY(U,$J,358.3,9003,0)
 ;;=R59.0^^45^431^66
 ;;^UTILITY(U,$J,358.3,9003,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9003,1,3,0)
 ;;=3^Enlarged Lymph Nodes,Localized
 ;;^UTILITY(U,$J,358.3,9003,1,4,0)
 ;;=4^R59.0
 ;;^UTILITY(U,$J,358.3,9003,2)
 ;;=^5019529
 ;;^UTILITY(U,$J,358.3,9004,0)
 ;;=C83.59^^45^431^108
 ;;^UTILITY(U,$J,358.3,9004,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9004,1,3,0)
 ;;=3^Lymphoblastic Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,9004,1,4,0)
 ;;=4^C83.59
 ;;^UTILITY(U,$J,358.3,9004,2)
 ;;=^5001590
 ;;^UTILITY(U,$J,358.3,9005,0)
 ;;=C83.50^^45^431^109
 ;;^UTILITY(U,$J,358.3,9005,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9005,1,3,0)
 ;;=3^Lymphoblastic Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,9005,1,4,0)
 ;;=4^C83.50
 ;;^UTILITY(U,$J,358.3,9005,2)
 ;;=^5001581
 ;;^UTILITY(U,$J,358.3,9006,0)
 ;;=C43.9^^45^431^112
 ;;^UTILITY(U,$J,358.3,9006,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9006,1,3,0)
 ;;=3^Malig Melanoma of Skin,Unspec Site
 ;;^UTILITY(U,$J,358.3,9006,1,4,0)
 ;;=4^C43.9
 ;;^UTILITY(U,$J,358.3,9006,2)
 ;;=^5001015
 ;;^UTILITY(U,$J,358.3,9007,0)
 ;;=C31.9^^45^431^113
 ;;^UTILITY(U,$J,358.3,9007,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9007,1,3,0)
 ;;=3^Malig Neop Accessory Sinus,Unspec
 ;;^UTILITY(U,$J,358.3,9007,1,4,0)
 ;;=4^C31.9
 ;;^UTILITY(U,$J,358.3,9007,2)
 ;;=^5000953
 ;;^UTILITY(U,$J,358.3,9008,0)
 ;;=C24.1^^45^431^115
 ;;^UTILITY(U,$J,358.3,9008,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9008,1,3,0)
 ;;=3^Malig Neop Ampulla of Vater
 ;;^UTILITY(U,$J,358.3,9008,1,4,0)
 ;;=4^C24.1
 ;;^UTILITY(U,$J,358.3,9008,2)
 ;;=^267100
 ;;^UTILITY(U,$J,358.3,9009,0)
 ;;=C21.0^^45^431^116
 ;;^UTILITY(U,$J,358.3,9009,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9009,1,3,0)
 ;;=3^Malig Neop Anus,Unspec
 ;;^UTILITY(U,$J,358.3,9009,1,4,0)
 ;;=4^C21.0
 ;;^UTILITY(U,$J,358.3,9009,2)
 ;;=^5000930
 ;;^UTILITY(U,$J,358.3,9010,0)
 ;;=C67.9^^45^431^119
 ;;^UTILITY(U,$J,358.3,9010,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9010,1,3,0)
 ;;=3^Malig Neop Bladder,Unspec
 ;;^UTILITY(U,$J,358.3,9010,1,4,0)
 ;;=4^C67.9
 ;;^UTILITY(U,$J,358.3,9010,2)
 ;;=^5001263
 ;;^UTILITY(U,$J,358.3,9011,0)
 ;;=C71.9^^45^431^123
